Hsa_circ_0046263 functions as a ceRNA to promote nasopharyngeal carcinoma progression by upregulating IGFBP3.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
23 07 2020
Historique:
received: 25 02 2020
accepted: 13 07 2020
revised: 08 07 2020
entrez: 25 7 2020
pubmed: 25 7 2020
medline: 26 3 2021
Statut: epublish

Résumé

Accumulating evidences indicate that circular RNAs (circRNAs), a subclass of noncoding RNAs, play important role in regulating gene expression in eukaryotes. Hsa_circ_0046263 (circ-0046263) was found aberrantly expressed in nasopharyngeal carcinoma (NPC), but its role in tumor growth and metastasis remains largely unclear. Sanger sequencing, RNase R assay, and nucleic acid electrophoresis were conducted to verify the identification of circ-0046263. Nuclear separation and fluorescence in situ hybridization (FISH) assays were used to determine the localization of circ-004263. Dual luciferase reporter and RNA immunoprecipitation (RIP) were employed to confirm the binding of circ-0046263 with miR-133a-5p. Colony formation, proliferation, wound healing, transwell, western blot, and in vivo tumor growth and metastasis assays were performed to assess the roles of circ-0046263, miR-133a-5p, IGFBP3 and their interactions in NPC cells. Circ-0046263 was upregulated in both NPC cell lines and tissues. The in vitro functional studies revealed that knockdown of circ-0046263 inhibited the proliferation, invasion, and migration of NPC cells, whereas its overexpression produced the opposite result. In vivo experiments indicated that knockdown or overexpression of circ-0046263 attenuated or promoted tumor growth and metastasis, respectively. Mechanistically, circ-0046263 could act as a miRNA sponge to absorb miR-133a-5p and upregulate the expression of miRNA downstream target IGFBP3. In addition, miR-133a-5p inhibition or IGFBP3 overexpression could rescue the malignant behavior induced by circ-0046263 silencing. Finally, circ-0046263 plays a tumor-promoting role in NPC to enhance malignant behavior through the miR-133a-5p/IGFBP3 axis, which could be a potential target for NPC therapy.

Identifiants

pubmed: 32703944
doi: 10.1038/s41419-020-02785-3
pii: 10.1038/s41419-020-02785-3
pmc: PMC7378203
doi:

Substances chimiques

IGFBP3 protein, human 0
Insulin-Like Growth Factor Binding Protein 3 0
MIRN133 microRNA, human 0
MicroRNAs 0
RNA, Circular 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

562

Références

Chen, Y. P. et al. Nasopharyngeal carcinoma. Lancet394, 64–80 (2019).
doi: 10.1016/S0140-6736(19)30956-0
Lee, H. M., Okuda, K. S., Gonzalez, F. E. & Patel, V. Current perspectives on nasopharyngeal carcinoma. Adv. Exp. Med. Biol.1164, 11–34 (2019).
doi: 10.1007/978-3-030-22254-3_2
Perri, F. et al. Management of recurrent nasopharyngeal carcinoma: current perspectives. OncoTargets Ther.12, 1583–1591 (2019).
doi: 10.2147/OTT.S188148
Lee, A. W. M. et al. Management of locally recurrent nasopharyngeal carcinoma. Cancer Treat. Rev.79, 101890 (2019).
doi: 10.1016/j.ctrv.2019.101890
Lee, A. W., Ma, B. B., Ng, W. T. & Chan, A. T. Management of nasopharyngeal carcinoma: current practice and future perspective. J. Clin. Oncol.33, 3356–3364 (2015).
doi: 10.1200/JCO.2015.60.9347
Zhang, H. D., Jiang, L. H., Sun, D. W., Hou, J. C. & Ji, Z. L. CircRNA: a novel type of biomarker for cancer. Breast Cancer25, 1–7 (2018).
doi: 10.1007/s12282-017-0793-9
Yin, Y. et al. Emerging roles of circRNA in formation and progression of cancer. J. Cancer10, 5015–5021 (2019).
doi: 10.7150/jca.30828
Verduci, L., Strano, S., Yarden, Y. & Blandino, G. The circRNA-microRNA code: emerging implications for cancer diagnosis and treatment. Mol. Oncol.13, 669–680 (2019).
doi: 10.1002/1878-0261.12468
Li, R. et al. CircRNA: a rising star in gastric cancer. Cell. Mol. Life Sci. https://doi.org/10.1007/s00018-019-03345-5 (2019).
Harper, K. L., McDonnell, E. & Whitehouse, A. CircRNAs: From anonymity to novel regulators of gene expression in cancer (Review). Int. J. Oncol.55, 1183–1193 (2019).
pubmed: 31661122
Chen, L. L. The biogenesis and emerging roles of circular RNAs. Nat. Rev. Mol. Cell Biol.17, 205–211 (2016).
doi: 10.1038/nrm.2015.32
Yu, C. Y. et al. The circular RNA circBIRC6 participates in the molecular circuitry controlling human pluripotency. Nat. Commun.8, 1149 (2017).
doi: 10.1038/s41467-017-01216-w
Wang, K. et al. Circular RNA mediates cardiomyocyte death via miRNA-dependent upregulation of MTP18 expression. Cell Death Differ.24, 1111–1120 (2017).
doi: 10.1038/cdd.2017.61
Chen, X. B., Li, W. & Chu, A. X. MicroRNA-133a inhibits gastric cancer cells growth, migration, and epithelial-mesenchymal transition process by targeting presenilin 1. J. Cell. Biochem.120, 470–480 (2019).
doi: 10.1002/jcb.27403
Liu, S., Chen, J., Zhang, T. & Chen, H. MicroRNA-133 inhibits the growth and metastasis of the human lung cancer cells by targeting epidermal growth factor receptor. J. BUON24, 929–935 (2019).
pubmed: 31424644
Li, T. F., Liu, J. & Fu, S. J. The interaction of long non-coding RNA MIAT and miR-133 play a role in the proliferation and metastasis of pancreatic carcinoma. Biomed. Pharmacother. = Biomed. Pharmacother.104, 145–150 (2018).
doi: 10.1016/j.biopha.2018.05.043
Hao, W. et al. Propofol protects against hepatic ischemia/reperfusion injury via miR-133a-5p regulating the expression of MAPK6. Cell Biol. Int.41, 495–504 (2017).
doi: 10.1002/cbin.10745
Almobarak, A. A., Jebreel, A. B. & Abu-Zaid, A. Molecular targeted therapy in the management of recurrent and metastatic nasopharyngeal carcinoma: a comprehensive literature review. Cureus11, e4210 (2019).
pubmed: 31114729 pmcid: 6505721
Zang, J., Lu, D. & Xu, A. The interaction of circRNAs and RNA binding proteins: an important part of circRNA maintenance and function. J. Neurosci. Res.98, 87–97 (2020).
doi: 10.1002/jnr.24356
Ke, Z., Xie, F., Zheng, C. & Chen, D. CircHIPK3 promotes proliferation and invasion in nasopharyngeal carcinoma by abrogating miR-4288-induced ELF3 inhibition. J. Cell. Physiol.234, 1699–1706 (2019).
doi: 10.1002/jcp.27041
Zhong, Q., Huang, J., Wei, J. & Wu, R. Circular RNA CDR1as sponges miR-7-5p to enhance E2F3 stability and promote the growth of nasopharyngeal carcinoma. Cancer Cell Int.19, 252 (2019).
doi: 10.1186/s12935-019-0959-y
Sun, Z. et al. Regulatory mechanisms and clinical perspectives of circRNA in digestive system neoplasms. J. Cancer10, 2885–2891 (2019).
doi: 10.7150/jca.31167
Dori, M. & Bicciato, S. Integration of bioinformatic predictions and experimental data to identify circRNA-miRNA Associations. Genes10, 642 (2019).
Natsuizaka, M. et al. Hypoxia induces IGFBP3 in esophageal squamous cancer cells through HIF-1alpha-mediated mRNA transcription and continuous protein synthesis. FASEB J.26, 2620–2630 (2012).
doi: 10.1096/fj.11-198598
Natsuizaka, M. et al. IGFBP3 promotes esophageal cancer growth by suppressing oxidative stress in hypoxic tumor microenvironment. Am. J. Cancer Res.4, 29–41 (2014).
pubmed: 24482736 pmcid: 3902230
Xue, M. et al. IGFBP3, a transcriptional target of homeobox D10, is correlated with the prognosis of gastric cancer. PLoS ONE8, e81423 (2013).
doi: 10.1371/journal.pone.0081423
Wang, W. et al. Meta-analysis of the association of IGFBP3 and IGF1 polymorphisms with susceptibility to colorectal cancer. Neoplasma65, 855–864 (2018).
doi: 10.4149/neo_2018_170720N491
Chan, Y. X. et al. Higher IGFBP3 is associated with increased incidence of colorectal cancer in older men independently of IGF1. Clin. Endocrinol.88, 333–340 (2018).
doi: 10.1111/cen.13499
Yoneyama, T. et al. Identification of IGFBP2 and IGFBP3 as compensatory biomarkers for CA19-9 in early-stage pancreatic cancer using a combination of antibody-based and LC-MS/MS-based proteomics. PLoS ONE11, e0161009 (2016).
doi: 10.1371/journal.pone.0161009
Prager, A. J. et al. Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer. Biomark. Med.7, 831–841 (2013).
doi: 10.2217/bmm.13.112
Mayo, J. C. et al. IGFBP3 and MAPK/ERK signaling mediates melatonin-induced antitumor activity in prostate cancer. J. Pineal Res.62, e12373 (2017).
Cao, Y. et al. Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival. J. Natl. Cancer Inst.106, dju085 (2014).
doi: 10.1093/jnci/dju218
Fan, X. et al. B-Myb mediates proliferation and migration of non-small-cell lung cancer via suppressing IGFBP3. Int. J. Mol. Sci.19, 1479 (2018).
Chen, S. et al. Relationship between IGF2BP2 and IGFBP3 polymorphisms and susceptibility to non-small-cell lung cancer: a case-control study in Eastern Chinese Han population. Cancer Manag. Res.10, 2965–2975 (2018).
doi: 10.2147/CMAR.S169222
Sun, Y., Ai, X., Shen, S., Gu, L. & Lu, S. Detection and correlation analysis of serum cytokines in non-small-cell lung cancer patients with bone and non-bone metastases. Patient Preference Adher.9, 1165–1169 (2015).
Yen, Y. C. et al. Insulin-like growth factor-independent insulin-like growth factor binding protein 3 promotes cell migration and lymph node metastasis of oral squamous cell carcinoma cells by requirement of integrin beta1. Oncotarget6, 41837–41855 (2015).
doi: 10.18632/oncotarget.5995
Bao, L. et al. Overexpression of IGFBP3 is associated with poor prognosis and tumor metastasis in nasopharyngeal carcinoma. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med.37, 15043–15052 (2016).
doi: 10.1007/s13277-016-5400-8
Gonzalez, D. M. & Medici, D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci. Signal.7, re8 (2014).
doi: 10.1126/scisignal.2005189
Yang, L. et al. Up-regulation of insulin-like growth factor binding protein-3 is associated with brain metastasis in lung adenocarcinoma. Mol. Cells42, 321–332 (2019).
pubmed: 31085806 pmcid: 6530643
Natsuizaka, M. et al. Insulin-like growth factor-binding protein-3 promotes transforming growth factor-{beta}1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells. Carcinogenesis31, 1344–1353 (2010).
doi: 10.1093/carcin/bgq108

Auteurs

Li Yin (L)

The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.

Jie Chen (J)

The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.
Xuzhou Medical University, Xuzhou, Jiangsu, China.

Chengxian Ma (C)

The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.

Shuai Pei (S)

The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.
Xuzhou Medical University, Xuzhou, Jiangsu, China.

Mingyu Du (M)

The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.

Yufeng Zhang (Y)

The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.

Yong Feng (Y)

The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.

Rong Yin (R)

The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.

Xiuhua Bian (X)

The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.

Xia He (X)

The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China. hexiabm@163.com.
Xuzhou Medical University, Xuzhou, Jiangsu, China. hexiabm@163.com.

Jifeng Feng (J)

The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China. jifeng_feng@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH